Non-invasive, controlled, and sustained release back-of-the-eye therapeutics for sight-threatening diseases such as: severe uveitis, diabetic macular edema, and age-related macular degeneration (AMD)
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of Aciont plus 4970 other startups.
